Prescriber's Guide to Lasmiditan
In October 2019, the FDA approved Eli Lilly's lasmiditan, marketed as Reyvow, for the acute treatment of migraine with or without aura in adults. The drug is the first approved from a new class of serotonin (5-HT)1F receptor agonists. This downloadable PDF serves as a convenient, consolidated prescribing guide to help you incorporate this new migraine therapy into your clinical practice.
October 12th 2020, 10:00 am EDT
11 Essential Neurology Guideline Updates
This downloadable PDF provides you with the most recent updates to key clinical guidelines for the treatment of various neurologic disorders. The guide includes new and updated guideline recommendations from US-, Canadian-, and European-based organizations on management of tic disorders, ischemic stroke, Parkinson disease, pediatric migraine, trigeminal neuralgia, and more.
October 11th 2020, 10:00 am EDT
A Physician's Guide to Critical Neurology Conditions eBook
This eBook takes an in-depth look into the NeurologyLive® clinical focus coverage across a variety of media platforms. This resource covers breaking news, interviews with top experts and coverage of FDA approvals.
October 8th 2020, 10:00 am EDT